Heart Valve Failure

Two scientist have developed a new hybrid tissue-engineered heart valve that combines a patient’s cells with metal alloy for more durability and possibly less complications which should be ready for use in about 10 to 15 years. The existing valve replacements are either mechanical or bioprosthetic which have great long-term risks of blood clots, stroke, clots in the artery, bleeding from the medicine to prevent artery clots, and limited durability. The current tissue oriented valves are meant to degrade the scaffold which can cause valve failure. The new heart valve is to become a living replacement of the damaged valve. This new hybrid technology should better a patient’s life by removing needed lifelong medication and not weaken the valve’s